About this episode

The episode discusses significant findings from the ESMO 2025 regarding bladder cancer treatment and their implications for clinical practice.

Survival data from the KEYNOTE-905 trial and insights into the use of circulating tumor DNA to guide treatment decisions from IMvigor011 made big waves in bladder cancer care at the European Society of Medical Oncology Annual Congress. “Overall, this is going to change the standard of care for muscle-invasive bladder cancer,” says Amanda Nizam, MD, a genitourinary medical oncologist at the Cleveland Clinic Taussig Cancer Institute. She and Robert A. Figlin, MD, the interim director of Cedars-Sinai Cancer in Los Angeles and Steven Spielberg Family Chair in Hematology-Oncology, discuss how the findings are being incorporated into clinic and what questions remain. “I am continually surprised by the changes taking place in bladder cancer management,” notes Dr. Figlin. Dr. Nizam reported various financial relationships. Dr. Figlin reported various financial relationships.

People in this episode

Guests: Amanda Nizam, MD, Robert A. Figlin, MD

Topics covered

• bladder cancer
• oncology
• clinical trials
• treatment decisions
• standard of care

Keywords

• bladder cancer
• KEYNOTE-905
• IMvigor011
• treatment decisions
• survival data
• oncology
• ESMO 2025

Mentioned in this episode

Organizations: Cleveland Clinic Taussig Cancer Institute, Cedars-Sinai Cancer

Products: KEYNOTE-905 trial, IMvigor011

More episodes of Oncology News Central Peer-Spectives

• New Targeted Therapies Make Breast Cancer Treatment Decisions “a Bit of a Moving Target” · April 21, 2026 · 9 min
• Advances in ESR1-Mutated Breast Cancer Care Lead to “Complex Situation” in Clinic · April 17, 2026 · 12 min
• Tackling “the Biggest Question That Everyone Is Asking” in Breast Cancer Care · April 2, 2026 · 14 min
• Shared Decision Making and Toxicity Management in EGFR- Mutated Advanced NSCLC · December 18, 2025 · 12 min
• “Where the Real Answer Lies”: How CNS Disease Influences EGFR-Mutated NSCLC Treatment Decisions · December 18, 2025 · 15 min
• “Is the Juice Worth the Squeeze?”: Treatment Intensification for Advanced EGFRm NSCLC · December 16, 2025 · 13 min

Explore listener stats, chart rankings, contacts and more on the Oncology News Central Peer-Spectives podcast page.